Invesco Nasdaq Biotechnology ETF
$34.60−0.80 (−2.26%)
- Expense ratio
- 0.19%
- Fund size
- $97M
- 1Y return
- +48.9%
- Yield · Last 12 months
- 1.11%
- Holdings
- 248
- Volume · 30D
- 0M sh
- NAV per share
- $34.83
- 52W range
The ETF.net IBBQ Grade
Score 75 of 100 sits in the A band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.AScore 100Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.AScore 85Category rankRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 66Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.CScore 45Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.BScore 62Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.DScore 39Category rank
Our read on IBBQ
AThe broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.
The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.
Why people hold it
- At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
- Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
- Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
- Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.
Worth knowing
- Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
- One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
- Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.
IBBQ Holdings
- Stocks
- 248
- 45%
- AMGN
Sectors
- Health Care99.9%
- Financials0.1%
Geography
- United States88.22%
- United Kingdom2.59%
- Netherlands2.37%
- Ireland1.66%
- Switzerland1.16%
- Denmark1.15%
- France1.07%
- Germany0.75%
- 1.02%
IBBQ Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | IBBQ |
|---|---|
| Year to date | +25.8% |
| 1 month | −1.8% |
| 3 months | +16.8% |
| 1 year | +48.9% |
| 3 years | +22.7% |
| 5 years | +6.9% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | IBBQ |
|---|---|---|
| 2026 YTD | +25.8% | |
| 2025 | +33.3% | |
| 2024 | −0.6% | |
| 2023 | +4.7% | |
| 2022 | −10.4% | |
| 2021 | −6.7% |
IBBQ in the news
ETF.net Research hasn’t filed on IBBQ yet — coverage lands here as it’s written.
IBBQ Dividends
- 1.11%
- $0.39
- $0.23 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Sep 21, 2026 | Pays Sep 25, 2026 | $0.23 |
| Jun 22, 2026 | Jun 26, 2026 | $0.03 |
| Mar 23, 2026 | Mar 27, 2026 | $0.04 |
| Dec 22, 2025 | Dec 26, 2025 | $0.09 |
| Sep 22, 2025 | Sep 26, 2025 | $0.10 |
| Jun 23, 2025 | Jun 27, 2025 | $0.03 |
| Mar 24, 2025 | Mar 28, 2025 | $0.04 |
| Dec 23, 2024 | Dec 27, 2024 | $0.06 |
| Sep 23, 2024 | Sep 27, 2024 | $0.09 |
| Jun 24, 2024 | Jun 28, 2024 | $0.05 |
| Mar 18, 2024 | Mar 22, 2024 | $0.04 |
| Dec 18, 2023 | Dec 22, 2023 | $0.05 |
IBBQ Risk
- 17.7%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.90
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −37.2%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.61
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
IBBQ Cost
- The middle half of Biotech & Genomics funds
- Median 0.47%
No Biotech & Genomics fund charges less.